← ZEVRA THERAPEUTICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $12.8m |
$13.3m
+3.50%
|
$28.6m
+115.61%
|
$10.5m
-63.50%
|
$27.5m
+162.58%
|
$23.6m
-14.02%
|
$106.5m
+350.91%
|
$136.1m
+27.80%
|
|
| Cost of Revenue | — | — | $0 | $10.0m |
$11.0m
+9.76%
|
$12.2m
+11.33%
|
$343k
-97.19%
|
$2.9m
+758.60%
|
$7.4m
+151.85%
|
$16.5m
+122.22%
|
$6.2m
-62.50%
|
|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | — | — | — | — | — | — | — | — | $7.4m |
$16.5m
+122.22%
|
$6.2m
-62.50%
|
|
| Cost of product revenue (excluding $X and $X in intangible asset amortization for the years ended XXX XX, 20XX, and 20XX, respectively, shown separately below) | — | — | — | — | — | — | — | $2.2m |
$7.4m
+241.33%
|
$16.5m
+122.22%
|
— | |
| Gross Profit | — | — | $0 | $2.8m |
$2.3m
-18.56%
|
$16.4m
+610.64%
|
$10.1m
-38.44%
|
$24.5m
+142.37%
|
$16.2m
-33.94%
|
$90.0m
+455.65%
|
$129.9m
+44.34%
|
|
| Research and Development Expense | $20.5m | $20.6m | $41.8m | $19.4m | $8.8m | $10.2m | $19.6m | $39.8m | $42.1m | $12.7m | $14.9m | |
| Selling, General and Administrative Expense | — | — | — | — | — | — | $15.0m | $34.3m | $54.9m | $77.6m | $74.6m | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | $800k | $6.2m | $3.9m | — | |
| Operating Expenses | $37.5m | $33.4m | $55.9m | $33.2m | $18.9m | $20.9m | $53.0m | $77.1m | $97.0m | $90.4m | $90.8m | |
| Loss from operations | ($37.5m) |
($33.4m)
+10.98%
|
($55.9m)
-67.54%
|
($20.3m)
+63.62%
|
($5.6m)
+72.42%
|
$7.7m
+237.80%
|
($42.5m)
-649.94%
|
($49.6m)
-16.70%
|
($87.0m)
-75.40%
|
($62.9m)
+27.65%
|
— | |
| Operating Income (Loss) | ($16.5m) |
($33.4m)
-101.84%
|
($55.9m)
-67.54%
|
($20.3m)
+63.62%
|
($5.6m)
+72.42%
|
$7.7m
+237.80%
|
($42.5m)
-649.94%
|
($49.6m)
-16.70%
|
($87.0m)
-75.40%
|
($62.9m)
+27.65%
|
$39.1m
+162.07%
|
|
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | — | $91k | $198k | ($219k) | ($1.5m) | — | |
| Gain on sale of PRV | — | — | — | — | — | — | — | — | $0 | $148.3m | — | |
| Interest and Other Income | $353k | $365k | $420k | $309k | $89k | $248k | $760k | $4.5m | $2.2m | $6.9m | — | |
| Interest Expense (non-operating) | — | $5.8m | $5.5m | $4.9m | $4.8m | $226k | $335k | $1.5m | $7.4m | $8.0m | $5.7m | |
| Total other income (expense) | $21.0m | ($10.1m) | ($689k) | ($4.2m) | ($7.2m) | ($16.2m) | $176k | $3.6m | ($3.1m) | $149.6m | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | — | — | $27.1m | $69.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($16.5m) | ($43.4m) | ($56.6m) | ($24.5m) | ($12.8m) | ($8.5m) | ($42.3m) | ($46.0m) | ($90.1m) | $86.7m | $69.3m | |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | — | — | — | — | $13.3m | $11.0m | |
| Income Tax Expense (Benefit) | $15k | ($43k) | ($126k) | ($22k) | ($34k) | $34k | ($786k) | $0 | $15.4m | $3.4m | $11.0m | |
| Net Income (Loss) Attributable to Parent | ($16.5m) |
($43.4m)
-162.69%
|
($56.5m)
-30.15%
|
($24.5m)
+56.57%
|
($12.8m)
+47.97%
|
($8.6m)
+32.95%
|
($41.5m)
-385.60%
|
($46.0m)
-10.85%
|
($105.5m)
-129.13%
|
$83.2m
+178.88%
|
$58.3m
-30.00%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | ($16.5m) |
($43.4m)
-162.69%
|
($56.5m)
-30.15%
|
($24.5m)
+56.57%
|
($12.8m)
+47.97%
|
($62.9m)
-392.92%
|
($41.5m)
+33.95%
|
($46.0m)
-10.85%
|
($105.5m)
-129.13%
|
$77.6m
+173.53%
|
$58.3m
-24.90%
|
|
| Preferred Stock Dividends and Other Adjustments | — | — | — | — | — | $54.3m | $0 | — | — | — | — | |
| Preferred Stock Dividends, Income Statement Impact | — | — | — | — | — | $54.3m | $0 | — | — | $0 | — | |
| Earnings Per Share, Basic | — | — | — | — | ($3.21) | ($2.11) | ($1.20) | ($1.30) | ($2.28) | $1.40 | $0.96 | |
| Earnings Per Share, Diluted | ($1.13) | ($2.96) | ($3.15) | ($0.83) | ($3.21) | ($2.11) | — | — | ($2.28) | $1.35 | $0.93 | |
| Basic (in shares) | — | — | — | — | $4.0m | $29.8m | $34.5m | $35.5m | $46.3m | $55.3m | $57.5m | |
| Diluted (in shares) | — | — | — | — | $4.0m | $29.8m | — | — | $46.3m | $57.3m | $59.6m | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | $4.0m | 29.8m | 34.5m | 35.5m | 46.3m | 55.3m | 57.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 29.8m | — | — | — | 57.3m | 59.6m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | $37.5m | $33.4m | $55.9m | $33.2m | $18.9m | $20.9m | $53.0m | $77.1m | $97.0m | $90.4m | — | |
| Goodwill, Impairment Loss | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | |
| Intangible asset amortization | — | — | — | — | — | — | — | $772k | $6.2m | $3.9m | — | |
| Impairment of intangible assets | — | — | — | — | — | — | — | — | $0 | $58.7m | — | |
| Fair value adjustment related to warrant and CVR liability | — | — | — | — | — | — | — | ($98k) | $2.1m | $2.2m | — | |
| Fair value adjustment related to investments | — | — | — | — | — | ($13k) | ($577k) | $613k | ($18k) | $149k | — |